Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.
about
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownDistinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virusPhase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected SubjectsEvolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targetsMultiple dendritic cell populations activate CD4+ T cells after viral stimulation.Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigsChimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.Recent progress in herpes simplex virus immunobiology and vaccine researchImmunoprotectivity of HLA-A2 CTL peptides derived from respiratory syncytial virus fusion protein in HLA-A2 transgenic mouseLatent infection with herpes simplex virus is associated with ongoing CD8+ T-cell stimulation by parenchymal cells within sensory gangliaAge-related dysregulation of CD8+ T cell memory specific for a persistent virus is independent of viral replicationDiversity of the CD8+ T cell repertoire elicited against an immunodominant epitope does not depend on the context of infection.Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infectionInduction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells.Immunodomination during peripheral vaccinia virus infection.Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus.Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in miceThe herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanismSingle and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal modelsPhenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpesKiller T cells regulate antigen presentation for early expansion of memory, but not naive, CD8+ T cellIdentification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell responseDefining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 miceLong-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation.Herpes simplex virus-2 glycoprotein interaction with HVEM influences virus-specific recall cellular responses at the mucosa.The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells.Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine VectorsTargeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses.Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.Antiviral immune responses in the genital tract: clues for vaccines.In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.Psychological stress impairs the local CD8+ T cell response to mucosal HSV-1 infection and allows for increased pathogenicity via a glucocorticoid receptor-mediated mechanism.Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2
P2860
Q21296712-C129FA25-FFAA-4ABB-A658-ED95BCF07B80Q24564228-40A21BBE-8A89-4EF2-B011-29E24FB35E8BQ27486108-CFC69F7A-35B6-4B70-8A1E-12FFC4D5564FQ30366017-F2E3323B-2D9D-4821-9864-2BB868C4EEF1Q33321258-CF52B150-356F-43F4-846F-3B6F5661D481Q33755236-0F2DE7BB-86C9-4985-A806-177B7065E74CQ33815865-23E8391D-2067-4974-AFF6-3C6327ABB3F5Q33825931-D0BB01AD-F396-4203-9056-C8D7871387F6Q33908690-5B917EDD-3EB9-4CBB-9F0D-FA9EFE2214AEQ33963713-CFD9788E-219E-4344-AFAC-A8A185D4F2F3Q34043293-EB7E6A79-F08D-4019-B97C-866C21E38B9DQ34142760-E1284CC2-A168-4955-9669-C759496B65E7Q34165203-E70E8C2C-DFD4-4E15-A318-2F8F115C1CE1Q34165211-DD46EEF9-DA5F-4890-B129-A3DA71A11AB1Q34228659-0D2B4288-F186-498F-A069-018500C7802EQ34326744-4D9DF610-5922-4809-B21F-276FAECFDC69Q34340988-F56625FA-13EA-4C5F-98AB-6A6E07685ACFQ34472265-91609740-87D6-4690-A7BC-2D367D77FE75Q34697921-EA951355-CC72-424E-A6E9-0897144818ECQ34777218-5C8A140D-4CE5-4E9B-9C47-E3FA1F577CDFQ35076638-8EFEC369-D3D0-41B8-B268-74F0F945F015Q35193019-B71852E1-F478-465D-8C7C-5427776DFE45Q35271194-6886C345-F18D-4118-8E6F-C21E25F520F7Q35487893-BF994AFB-514A-479D-8E95-971E955E24DAQ35729822-0EDE910F-8ED7-4A00-8FBB-8150AF558426Q35802953-495E17E4-14FC-449E-904A-2B44A3D335DEQ35814043-4B579768-0638-418F-9A46-EB8946B5A30EQ35840599-8D4D7754-C7B0-4821-8676-2A850C2A81A7Q35935558-DD5BC20D-6F95-4D8F-8DD8-42845491B40EQ35986776-DB8043A1-A4EF-49BA-A0A1-E5F93DE724D3Q36005107-F9BDFFB1-E331-4E96-A269-98313FC85DD2Q36225280-460B26FA-B86F-4343-9C53-53850AB7F2BEQ36339059-B6B0C01F-2F8C-4757-9149-1D96600073A3Q36371702-C4DE1D10-3A97-44C7-90DC-5BE4F9FC568CQ36898071-99D7CF4F-1B40-4085-8C72-DD820C7FAD9EQ36918159-86000AC4-61DB-44C4-A924-394421F7352EQ36959354-BA9677BC-BAB8-450A-BB6B-0B7CDC21D2B2Q36982946-D635930F-0883-465A-9A10-09CBEED33D60Q37041318-A095BC6A-1DCD-42F0-B8F7-01CDCC352FBCQ37082143-FF6ADD50-D6AD-4616-9B4D-EEDA5AAA5EE7
P2860
Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Immunization with a single maj ...... 2 confers protective immunity.
@ast
Immunization with a single maj ...... 2 confers protective immunity.
@en
type
label
Immunization with a single maj ...... 2 confers protective immunity.
@ast
Immunization with a single maj ...... 2 confers protective immunity.
@en
prefLabel
Immunization with a single maj ...... 2 confers protective immunity.
@ast
Immunization with a single maj ...... 2 confers protective immunity.
@en
P2093
P2860
P1433
P1476
Immunization with a single maj ...... 2 confers protective immunity
@en
P2093
E Nobusawa
J E Blaney
R H Bonneau
S S Tevethia
P2860
P304
P577
1998-12-01T00:00:00Z